What we are missing 2012 KDIGO guideline. Anemia.

Slides:



Advertisements
Similar presentations
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
Advertisements

Anaemia management in people with chronic kidney disease
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
ANEMIA IN PREGNANCY O+G Update 2014 Hospital Sarikei.
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Update of Anemia management in chronic kidney disease What is still missing.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Journal Club EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.
KDIGO Clinical Practice Guideline Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD)
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)
Mario Cozzolino, MD, PhD NUOVE ACQUISIZIONI NELLA TERAPIA DELL’IPERPARATIROIDISMO SECONDARIO IN DIALISI PERITONEALE XV CONVEGNO del Gruppo di Studio di.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Anemia in chronic kidney disease
Epoetin Alfa & Increased Mortality Maria Shin, Pharm.D. Pharmacy Resident (PGY-1) Kingsbrook Jewish Medical Center Clinical Instructor of Pharmacy Practice.
ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.
Iron Repletion in ESRD Saleem Bharmal 2/9/10.
Nephrology Grand Rounds 5/13/08. Refractory Hyperparathyroidism Brad Weaver.
Case of the week Prof : Faiza Qari. T score of -2.5 in the lumbar spine  A 65 year old female was diagnosed to have osteoporosis (T score of -2.5 in.
Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.
Effect of cinacalcet on bone markers in a maintenance haemodialysis patient Solenn Pelletier, MD and Denis Fouque, MD, PhD Hôpital E. Herriot Lyon, France.
How to manage anaemia in HD patients
Chronic Kidney Disease-Mineral and Bone Disorder
Diagnosis and evaluation of anemia in CKD/HD
Adynamic Bone Disease Begins before Dialysis The 25 th Annual Dialysis Conference in Tampa Akihide Tokumoto, M.D. San-in Rosai Hospital, Yonago, Japan.
Calcium Homeostasis. 99% body calcium in skeleton 0.9 % intracellular 0.1% extracellular 50% bound Mostly albumin (alkalosis) Smaller amount phosphorous.
ANEMIA September 17 th, 2011 Debra Wells BSN, RN, CNN.
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
New NKF-K/DOQI guidelines Shahrzad Ossareh-M.D. Kidney Disease Outcome Quality Initiative.
Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
Acute and Chronic Renal Failure By Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Management of Anemia in CKD Patients 2012 KDIGO Update Dr. Shahram Taheri.
TREATMENT IRON DEFICIENCY ANEMIA. 3 Approaches in the Treatment of IDA: 1.Red Cell Transfusion 2.Oral Iron Therapy 3.Parenteral Iron Therapy Braunwald.
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
Secondary Hyperparathyroidism in CKD: Usefulness of VDR Agonists Reference: Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin d.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Erythropoietin for anemia of CRF.
CKD Treatment 순천향 대학교병원 신장내과 R3 김재연. Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal.
( 수 ) 신장내과 전임의 한선애 TREATING ANEMIA IN CKD.
Rayaldee® - calcifediol
Hepatitis B virus infection in renal transplant recipients
Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD
Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD
Acute and Chronic Renal Failure
Oral Phosphate Binders in Patients with Kidney Failure
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
MLAB Hematology Keri Brophy-Martinez
Mansoura International Hospital Mansoura International Hospital
Endocrine Disorders Parathyroid Gland
Warfarin Toxicity Treatment & Management
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
The ECHO Observational Study
KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients 순천향대학교 서울병원 신장내과 R2 김윤석.
Volume 67, Pages S1-S7 (June 2005)
Chapter 2: Clinical Indicators and Preventive Care
Chronic kidney disease and pre-dialysis
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
CPR 1.1. Identifying Patients and Initiating Evaluation
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
CKD Complications By Alaina Darby.
Bone metabolism and disease in chronic kidney disease
Volume 2: End-Stage Renal Disease
Guidelines American Journal of Kidney Diseases
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Diseases of the Renal System
Diseases of the Renal System
CKD Is a Global Burden With Major Implications
Presentation transcript:

What we are missing 2012 KDIGO guideline

Anemia

Diagnosis and evaluation  Hb measurement - CKD patient with anemia  CKD 3-5ND, CKD 5PD : at least every 3months  CKD 5HD : at least monthly  Initial evaluation of the anemia  Complete blood count  Reticulocyte count  Serum ferritin level  Serum transferrin saturation  Serum vitamin B 12, folate level

Use of iron to treat  Untreated iron deficiency is an important cause of hyporesponsiveness to ESA treatment  For adult CKD patients on ESA therapy who are not receiving iron supplementation, we suggest a trial of IV iron (or in CKD ND patients alternatively a 1–3 month trial of oral iron therapy)  TSAT ≤ 30% and ferritin ≤ 500 ng/ml  CKD ND, CKD PD : oral or IV  CKD 5HD : IV iron → greater increase in Hb, lower ESA dose  Course of IV iron amounting to approximately 1000 mg (VENOF 100mg, 10 회 )  Initial dose of IV iron administered, we recommend that patients be monitored for 60 minutes after the infusion  Avoid administering IV iron to patients with active systemic infections

Use of ESAs and other agents  Address all correctable causes of anemia (iron deficiency, inflammatory states) prior to initiation of ESA therapy  Caution : active malignancy, history of stroke, malignancy  CKD ND  Hb ≥ 10 g/dl : ESA therapy not be initiated  Hb < 10g/dl : initiate ESA therapy be individualized  CKD 5D  ESA therapy be used to avoid having the Hb < 9 g/dl  ESAs not be used to intentionally increase the Hb >13 g/dl  Stroke, hypertension, vascular access thrombosis ↑

ESA dosing and maintenance  Initial ESA dose : Hb concentration, body weight, clinical circumstances  Epoetin-alfa or epoetin-beta : IU/kg, 3 times/week  Darbepoetin-alfa : 0.45 mg/kg, once weekly (SC or IV) or 0.75 mg/kg, every 2 weeks (SC)  CERA : 0.6 mg/kg, every 2 weeks (SC or IV), or 1.2 mg/kg, every 4 weeks (SC)  Lower dose : history of CVD, thromboembolism, seizures, high blood pressure  Rise in Hb of greater than 2.0 g/dl over a 4-week period should be avoided  CKD ND, CKD 5PD : SC  CKD 5HD : IV or SC (efficacy : SC > IV)

ESA hyporesponsiveness  ESA hyporesponsiveness  No increase in Hb concentration from baseline after the first month of ESA treatment on appropriate weight-based dosing  Avoiding repeated escalations in ESA dose beyond double the initial weight-based dose

Pure red cell aplasia  Patient receiving ESA therapy for more than 8 weeks  Sudden rapid decrease in Hb concentration at the rate of g/dl per week or requirement of transfusions at the rate of approximately 1-2 per week  Normal platelet and white cell counts  Absolute reticulocyte count < 10,000/ml  We recommend ESA therapy be stopped in patients who develop antibody-mediated PRCA  We recommend peginesatide (synthetic, peptide-based erythropoietin-receptor agonist) be used to treat patients with antibody-mediated PRCA

Red cell transfusion to treat anemia in CKD  Managing chronic anemia, we recommend avoiding red cell transfusions  In patients eligible for organ transplantation, we specifically recommend avoiding  Indication  ESA therapy is ineffective (e.g., hemoglobinopathies, bone marrow failure, ESA resistance)  The risks of ESA therapy may outweigh its benefits (e.g., previous or current malignancy, previous stroke)

Red cell transfusion to treat anemia in CKD  HLA sensitization  post-leukodepletion era still continues to pose a significant risk of sensitization  Urgent treatment of anemia  Rapid correction of anemia is required to stabilize the patient’s condition (e.g., acute hemorrhage, unstable coronary artery disease)  When rapid pre-operative Hb correction is required  Considered if the Hb < 7 g/dl

CKD-MBD

Diagnosis of CKD–MBD  Monitor serum levels of calcium, phosphorus, PTH, alkaline phosphatase activity beginning in CKD stage 3  CKD stage 3  Ca/P : 6–12 months  PTH : based on baseline level and CKD progression  CKD stage 4  Ca/P : 3–6 months  PTH : 6–12 months  CKD stages 5, 5D  Ca/P : 1–3 months  PTH : 3–6 months  CKD stages 4–5D  ALP : 12 months, or more frequently in the presence of elevated PTH

Diagnosis of CKD–MBD  CKD stages 3–5D  25(OH)D (calcidiol) levels might be measured  Vitamin D deficiency and insufficiency should be corrected

Diagnosis of CKD–MBD: bone  CKD stages 3–5D : perform a bone biopsy  Unexplained fractures, persistent bone pain, unexplained hypercalcemia, unexplained hypophosphatemia, possible aluminum toxicity, prior to therapy with bisphosphonates in patients with CKD–MBD  Gold standard for the diagnosis of renal osteodystrophy  Provide measurements of bone turnover, mineralization, volume  Help to assess bone quality and the underlying physiology  CKD stages 3–5D : we suggest that BMD testing not be performed routinely  BMD does not predict fracture risk as it does in the general population  BMD does not predict the type of renal osteodystrophy

Diagnosis of CKD–MBD: vascular calcification  CKD stages 3–5  Lateral abdominal radiograph → vascular calcification  Echocardiogram → valvular calcification Bellasi A. et al. Kidney Int 70:1623–1628, 2006

Treatment of CKD–MBD  CKD stages 3–5D  Ca, P : normal range  Dialysate calcium concentration between mEq/l  Hyperphosphatemia : use phosphate-binding agents  HyperP with hyperCa : restrict calcium-based phosphate binders, calcitriol, vitamin D analog  HyperP with arterial calcification, adynamic bone disease, low serum PTH : restrict calcium-based phosphate binders  Avoid the long-term use of aluminum-containing phosphate binders

Treatment of abnormal PTH levels in CKD–MBD  CKD stages 3–5 not on dialysis, the optimal PTH level is not known  We suggest that patients with levels of intact PTH above the upper normal limit of the assay are first evaluated for hyperphosphatemia, hypocalcemia, and vitamin D deficiency  In patients with CKD stage 5D : iPTH levels - 2-9xUNL  no RCTs showing that treatment to achieve a specific PTH level results in improved outcomes

Treatment of abnormal PTH levels in CKD–MBD  CKD stage 5D : iPHT ↑  Calcitriol, vitamin D analogs, calcimimetics be used to lower PTH  HyperCa/P : calcitriol or another vitamin D sterol be reduced or stopped  HypoCa : calcimimetics be reduced or stopped  Intact PTH levels < 2xUNL : calcitriol, vitamin D analogs, calcimimetics be reduced or stopped  CKD stages 3–5D with severe hyperparathyroidism who fail to respond to medical/pharmacological therapy, we suggest parathyroidectomy

Evaluation and treatment of kidney transplant bone disease  In patients in the immediate post-kidney-transplant period, we recommend measuring serum calcium and phosphorus at least weekly, until stable  CKD stages 1–3T  Ca/P : 6-12 months  PTH : once with subsequent intervals depending on baseline level and CKD progression  CKD stage 4T  Ca/P : 3–6 months  PTH : 6–12 months  CKD stage 5T  Ca/P : 1–3 months  PTH : 3–6 months  CKD stages 3–5T  ALP : annually or more frequently in the presence of elevated PTH

Evaluation and treatment of kidney transplant bone disease  CKD stages 1–5T  25(OH)D (calcidiol) levels might be measured  Vitamin D deficiency and insufficiency be corrected  eGFR > 30 ml/min/1.73m 2  Measure BMD in the first 3 months after kidney transplant if they receive corticosteroids or have risk factors for osteoporosis as in the general population  Low BMD : treatment with vitamin D, calcitriol/alfacalcidol, or bisphosphonates be considered  CKD stages 4–5T  BMD testing not be performed routinely

1month lab

3 month

6 month

12 month

What we are missing?  25(OH)vitD  VitaminB 12, folate  Lateral abdominal radiograph  Echocardiography  Measure BMD in KT patient  Measure Ca/P immediate post-kidney-transplant period, at least weekly